Clene (CLNN) EBITDA Margin (2020 - 2026)
Clene (CLNN) posted EBITDA Margin of 5941.11% for Q2 2026, up 39.0% on a QoQ basis from 9740.26% in Q4 2025, and up 1591074.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Clene (CLNN) EBITDA Margin (2020 - 2026) Analysis & Trends
Clene has reported EBITDA Margin for 7 years, with the latest figure at 5941.11% in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 1591074.0% year-over-year to 5941.11% in Q2 2026; TTM through Jun 2026 was 11672.25%, a 241456.0% decrease from a year earlier, with the FY2025 full-year figure at 11550.0%, down 187164.0% from the prior year.
- EBITDA Margin was 5941.11% for Q2 2026 at Clene, up from 9740.26% in the prior quarter.
- The five-year high for EBITDA Margin was 3842.38% in Q2 2023, with the low at 44453.33% in Q1 2022.
- Average EBITDA Margin over 5 years is 14235.93%, with a median of 8982.76% recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin sank 3896038 bps in 2022, then jumped 3501476 bps in 2023.
- Over 5 years, EBITDA Margin stood at 4988.46% in 2022, then decreased by 17 bps to 5841.18% in 2023, then plunged by 63 bps to 9518.68% in 2024, then decreased by 2 bps to 9740.26% in 2025, then jumped by 39 bps to 5941.11% in 2026.
- The last three EBITDA Margin figures came in at 5941.11% (Q2 2026), 9740.26% (Q4 2025), and 37653.33% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 42.23% |
| 10 | Clene | 45.69 Mn | 45.69 Mn | 54,000.00 | -5,941.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,941.11% |
| Dec 31, 2025 | -9,740.26% |
| Sep 30, 2025 | -37,653.33% |
| Jun 30, 2025 | -21,851.85% |
| Mar 31, 2025 | -5,061.73% |
| Dec 31, 2024 | -9,518.68% |
| Sep 30, 2024 | -8,982.76% |
| Jun 30, 2024 | -8,131.87% |
| Mar 31, 2024 | -12,646.58% |
| Dec 31, 2023 | -5,841.18% |
| Sep 30, 2023 | -8,835.19% |
| Jun 30, 2023 | -3,842.38% |
| Mar 31, 2023 | -10,029.91% |
| Dec 31, 2022 | -4,988.46% |
| Sep 30, 2022 | -5,635.06% |
| Jun 30, 2022 | -38,857.14% |
| Mar 31, 2022 | -44,453.33% |
| Dec 31, 2021 | -7,075.38% |
| Sep 30, 2021 | -9,545.45% |
| Jun 30, 2021 | -6,865.67% |